Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV002294380 | SCV002587691 | pathogenic | Atypical hemolytic-uremic syndrome | 2022-07-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000786909 | SCV002776671 | pathogenic | Immunoglobulin-mediated membranoproliferative glomerulonephritis | 2022-05-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003558591 | SCV004297488 | pathogenic | not provided | 2024-12-03 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr204Asnfs*4) in the DGKE gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in DGKE are known to be pathogenic (PMID: 23274426, 23542698). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This premature translational stop signal has been observed in individual(s) with DGKE-related conditions (PMID: 25443527, 28526779). This variant is also known as c.790_791insA. ClinVar contains an entry for this variant (Variation ID: 635454). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV000786909 | SCV000925810 | pathogenic | Immunoglobulin-mediated membranoproliferative glomerulonephritis | 2018-12-03 | no assertion criteria provided | clinical testing |